Novel Class of Proteasome Inhibitors: In Silico and In Vitro Evaluation of Diverse Chloro(trifluoromethyl)aziridines.
Laura IeloVincenzo PatamiaAndrea CitarellaThomas EfferthNasim ShahhamzeheiTanja SchirmeisterClaudio StagnoThierry LangerAntonio RescifinaNicola MicaleVittorio PacePublished in: International journal of molecular sciences (2022)
The ubiquitin-proteasome pathway (UPP) is the major proteolytic system in the cytosol and nucleus of all eukaryotic cells. The role of proteasome inhibitors (PIs) as critical agents for regulating cancer cell death has been established. Aziridine derivatives are well-known alkylating agents employed against cancer. However, to the best of our knowledge, aziridine derivatives showing inhibitory activity towards proteasome have never been described before. Herein we report a new class of selective and nonPIs bearing an aziridine ring as a core structure. In vitro cell-based assays (two leukemia cell lines) also displayed anti-proliferative activity for some compounds. In silico studies indicated non-covalent binding mode and drug-likeness for these derivatives. Taken together, these results are promising for developing more potent PIs.
Keyphrases
- cell death
- papillary thyroid
- cell cycle arrest
- squamous cell
- molecular docking
- healthcare
- induced apoptosis
- single cell
- structure activity relationship
- bone marrow
- acute myeloid leukemia
- lymph node metastasis
- cell therapy
- high throughput
- emergency department
- stem cells
- oxidative stress
- childhood cancer
- cell proliferation
- mesenchymal stem cells
- binding protein
- drug induced
- molecular dynamics simulations